亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Clinical Impact of Neoantigen Burden and HLA Loss in Aggressive B-Cell Lymphomas Treated with CD19 CAR T-Cell

人类白细胞抗原 淋巴瘤 免疫学 嵌合抗原受体 生物 医学 免疫疗法 抗原 免疫系统
作者
Bachisio Ziccheddu,Michael D. Jain,Monika Chojnacka,Michael A. Durante,Julieta Abraham-Miranda,Meghan Menges,Ola Landgren,Marco L. Davila,Jonathan H. Schatz,Francesco Maura,Frederick L. Locke
出处
期刊:Blood [American Society of Hematology]
卷期号:142 (Supplement 1): 4362-4362
标识
DOI:10.1182/blood-2023-182821
摘要

INTRODUCTION: CD19-directed chimeric antigen receptor (CAR-19) T cells have revolutionized clinical outcomes in heavily pretreated patients with aggressive B-cell lymphoma. Notably, emerging evidence suggests that the efficacy of CAR-19 therapy extends beyond direct tumor killing and includes its ability to stimulate and guide the host immune system in the fight against tumor cells. To delve deeper into this crucial aspect, our study utilized whole-genome sequencing (WGS) data to explore the impact of neoantigen burden and HLA loss in patients with aggressive large B-cell lymphoma (rrLBCL) who received CAR-19 therapy (WGS; Jain et al. Blood 2022). METHODS: To characterize the importance of genomic immunogenicity in rrLBCL, we conducted a comprehensive analysis of 61 whole-genome sequencing (WGS) and 54 RNA sequencing samples from 54 rrLBCL patients who underwent CAR-19 therapy. Among these samples, 39 were collected at baseline and 15 at relapse, with samples from 7 patients obtained both before and after treatment. Our analytical workflow defined HLA class I mono- or biallelic loss by integrating copy number variants, structural variants, single nucleotide variants, and small insertion-deletion data with allele-specific HLA loss information obtained from LOHHLA software. pVACseq algorithm was used to predict the number of clonal neoantigens in each sample, along with the corresponding HLA allele presenting each of them. RESULTS: HLA class I loss was detected in 38.9% of the patients, with no impact on progression free survival (PFS). Interestingly 7 patients had biallelic loss of HLA-B, and all of them experienced progression within the first year (p=0.03). To expand our analysis, we explored B2M an essential component of HLA class I complexes. B2M was lost in 33.3% of the patients without showing any association with shorter PFS. However, restricting the analysis to patients with B2M biallelic loss (defined as presence of deletions of both alleles, or deletion and mutation with high impact in the structure and function of the B2M protein) 4/4 patients progressed. Overall, all 11 patients with genomic events leading to biallelic loss of HLA class I progressed (p=0.007). Notably, in one patient (CAR_39), biallelic inactivation of HLA class I was not detected at baseline but emerged with the dominant clone at disease progression. HLA class I biallelic loss was associated with genomic drivers previously identified in our study as significantly associated with CAR-19 failure: APOBEC (3/11) and SBS18 (oxygen radical stress; 2/11) mutational signatures, chromothripsis (4/11), RHOA deletions (6/11), and double minutes (4/11). Next, we analyzed the impact of the neoantigen burden corrected for their HLA affinity and allelic status on the outcome of CAR-19 treatment. Patients with high number of neoantigens had shorter PFS (p=0.0095) and were enriched for genomic drivers associated with poor response after CAR-19 (e.g., APOBEC and SBS18). Interestingly, the neoantigen burden had a bimodal distribution across patients that progressed with two distinct groups: one with high neoantigen burden, biallelic loss of HLA, and high genomic complexity and the other with low genomic complexity and low neoantigen burden. Restricting the analysis to patients with retained HLA and low genomic complexity, high neoantigen burden associated with prolonged and favorable response to CAR-T therapy (p=0.04). CONCLUSION: This study offers evidence that there is a critical relationship between CAR-19 efficacy, LBCL immunogenicity, and the endogenous immune response.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
gszy1975完成签到,获得积分10
13秒前
圆圆的波仔发布了新的文献求助100
23秒前
JamesPei应助科研通管家采纳,获得10
1分钟前
郗妫完成签到,获得积分10
1分钟前
2分钟前
郜南烟发布了新的文献求助10
2分钟前
Venus完成签到 ,获得积分10
3分钟前
在水一方应助chenyuns采纳,获得30
4分钟前
JACk完成签到 ,获得积分10
4分钟前
4分钟前
chenyuns发布了新的文献求助30
4分钟前
爱静静应助李伟采纳,获得10
4分钟前
4分钟前
zhangyimg发布了新的文献求助10
5分钟前
5分钟前
郜南烟发布了新的文献求助10
5分钟前
斯文败类应助郜南烟采纳,获得10
5分钟前
思源应助chenyuns采纳,获得20
5分钟前
Akim应助chenyuns采纳,获得20
6分钟前
领导范儿应助圆圆的波仔采纳,获得10
7分钟前
7分钟前
7分钟前
李爱国应助怕孤单的灵寒采纳,获得10
7分钟前
圆圆的波仔完成签到,获得积分10
7分钟前
7分钟前
7分钟前
怕孤单的灵寒完成签到,获得积分20
7分钟前
8分钟前
chenyuns发布了新的文献求助20
8分钟前
8分钟前
CZLhaust发布了新的文献求助10
8分钟前
8分钟前
Sherling发布了新的文献求助10
8分钟前
李爱国应助Sherling采纳,获得10
8分钟前
CZLhaust完成签到,获得积分10
8分钟前
8分钟前
jingjili发布了新的文献求助30
9分钟前
酷波er应助科研通管家采纳,获得10
9分钟前
9分钟前
郜南烟发布了新的文献求助10
9分钟前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
叶剑英与华南分局档案史料 500
Foreign Policy of the French Second Empire: A Bibliography 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3146771
求助须知:如何正确求助?哪些是违规求助? 2798063
关于积分的说明 7826621
捐赠科研通 2454573
什么是DOI,文献DOI怎么找? 1306394
科研通“疑难数据库(出版商)”最低求助积分说明 627708
版权声明 601527